IVIG
is a blood product which is administered in the body through veins.
These are used in the treatment of three major categories of diseases,
namely immune diseases, autoimmune diseases and acute infections. These
are administered in patients to maintain an optimum level of antibodies
so as to upgrade immunity or avoid infections. The factors driving this
market are increasing number of patients with bleeding disorders,
autoimmune diseases and asthma, increasing awareness and expenditure on
health products and technological developments. The resulting side
effects with the use of intravenous immunoglobulin such as venous
thrombosis, dermatitis and acute kidney disorders and high cost involved
in treatment are restraining the growth of this market. The
introduction of improved therapies for the treatment of these diseases
would provide opportunity for growth of this market.
Get detailed report at: http://www.reportsandintelligence.com/intravenous-immunoglobulin-IVIG-market
GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) APPLICATION MARKET ANALYSIS
On the basis of application, this market can be classified into neurology, haematology, dermatology, nephrology and ophthalmology. Among all areas where intravenous immunoglobulin is used, its application is maximum in heamatology. This is due to the increasing number of people with bleeding disorders.
On the basis of application, this market can be classified into neurology, haematology, dermatology, nephrology and ophthalmology. Among all areas where intravenous immunoglobulin is used, its application is maximum in heamatology. This is due to the increasing number of people with bleeding disorders.
INTRAVENOUS IMMUNOGLOBULIN (IVIG) GEOGRAPHY MARKET ANALYSIS
On the basis of geography, this market can be classified into North America, Europe, Asia-Pacific and rest of the world (RoW). Presently, North America is the major contributor to the market of IVIG followed by Europe. This is due to increasing number of people suffering from autoimmune diseases.
On the basis of geography, this market can be classified into North America, Europe, Asia-Pacific and rest of the world (RoW). Presently, North America is the major contributor to the market of IVIG followed by Europe. This is due to increasing number of people suffering from autoimmune diseases.
COMPETITIVE LANDSCAPE
The major players in this market are Biotest AG, Octapharma AG, CSL, Baxter International, Inc., Bharat Serums and Vaccines Ltd., Talecris, Grifols S.A., OMRIX Biopharmaceuticals Ltd, and Kedrion Biopharma. The companies in the report are seeking approval as a strategy for the commercialization of their in the pipeline drugs. Therefore, the companies are adopting approval and clearance as key developmental strategies.
The major players in this market are Biotest AG, Octapharma AG, CSL, Baxter International, Inc., Bharat Serums and Vaccines Ltd., Talecris, Grifols S.A., OMRIX Biopharmaceuticals Ltd, and Kedrion Biopharma. The companies in the report are seeking approval as a strategy for the commercialization of their in the pipeline drugs. Therefore, the companies are adopting approval and clearance as key developmental strategies.
No comments:
Post a Comment